Publications by authors named "Rieko Kiya"
This study aimed to investigate in detail the efficacy of switching from etanercept reference product (RP) to etanercept biosimilar in patients with rheumatoid arthritis (RA) under real-world clinical conditions using clinical indices and musculoskeletal ultrasound (MSUS). This interventional, multicenter, open-label, single-arm clinical trial involved 24- or 52-week follow-up. This study enrolled patients with RA who had been treated with etanercept-RP for ≥ 24 weeks, achieved clinical low disease activity (LDA) or remission, and switched from etanercept-RP to etanercept biosimilar.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of filgotinib, a selective JAK1 inhibitor, compared to tocilizumab, an interleukin-6 inhibitor, in treating rheumatoid arthritis (RA) patients who haven’t responded well to methotrexate (MTX).
- This is a multicenter, randomized, open-label clinical trial involving 400 participants, monitored over 52 weeks to assess disease activity and improvement.
- The primary goal is to determine if filgotinib can provide similar results to tocilizumab in reducing disease symptoms, measured by clinical indices and ultrasound, especially focusing on the proportion of patients reaching the American College of Rheumatology 50 response at week 12.
Article Synopsis
- - Lascufloxacin hydrochloride (LSFX) is a new quinolone antibiotic that effectively targets various bacteria, including those causing pneumonia, with a goal of reducing antibiotic resistance.
- - A study was conducted with 77 patients suffering from nursing and healthcare-associated pneumonia (NHCAP), where they received LSFX (75 mg daily for 7 days) to assess its clinical effectiveness and safety.
- - The results indicated that LSFX is both effective and safe for treating NHCAP, potentially providing more treatment options for this serious form of pneumonia.